Immunotherapy plus chemotherapy shows durable responses in lymph-node-dominant metastatic gallbladder cancer

Patients with metastatic gallbladder cancer whose disease is dominated by lymph-node spread showed striking responses to a combination of PD-1 immune checkpoint blockade and the chemotherapy pair gemcitabine plus nab-paclitaxel, according to a retrospective real-world study published in Cancer Immunology, Immunotherapy. In the series of 11 patients treated between 2020 and 2025 at two high-volume hepatobiliary centers in China, every patient experienced an objective radiographic response, and six achieved radiographic complete responses as assessed by RECIST version 1.1.

The survival figures reported in the study are notable for a disease with a notoriously poor prognosis once distant metastases develop. After a median follow-up of 26.8 months, the median overall survival had not been reached, and the 12-month overall survival rate stood at 100 percent. Median progression-free survival was 23.7 months.

The treatment was not without toxicity. Grade 3 or 4 adverse events, the severe categories on the standard grading scale, occurred in 7 of the 11 patients.

A distinctive feature of the study is its focus on a specific metastatic pattern rather than metastatic gallbladder cancer as a whole. The investigators proposed an exploratory four-type classification of metastatic disease based on the extent of the primary tumor, the distribution of tumor burden, and the metastatic pattern. To gather population-level corroboration of whether this classification discriminates prognosis, the team queried the Surveillance, Epidemiology, and End Results database, a large American cancer registry. The clinical series itself concentrated on the subgroup with lymph-node-dominant metastases, in which lymph nodes rather than distant organs carry the bulk of the metastatic tumor burden.

To explore why checkpoint blockade might work particularly well in this subgroup, the researchers performed an independent, exploratory single-cell transcriptomic analysis on a separate cohort of 12 patients with resectable gallbladder cancer. In this analysis, the team characterized the cellular composition and cell-to-cell communication networks of tumor-infiltrating cells.

The single-cell findings pointed to a more immunologically active microenvironment in lymph-node-positive disease. The authors present this analysis as providing a general rationale for checkpoint targeting in lymph-node-positive disease rather than as a direct explanation of the clinical outcomes in the treatment series.

The study was conducted as a multicenter retrospective analysis at Renji Hospital of Shanghai Jiao Tong University School of Medicine and Zhongshan Hospital Affiliated to Fudan University. Ethical approval came from the ethics committee of the research department at Renji Hospital, and the study was registered in the Chinese Clinical Trial Registry under identifier ChiCTR2200065916. The article was published open access on 27 October 2026 as a peer-reviewed, accepted research paper.

The authors are explicit that the evidence remains preliminary. Given the small size of the series, its uncontrolled and retrospective design, and the potential for selection bias in choosing which patients received the combination, conclusions about efficacy are limited, they write. Eleven patients treated at specialized centers, however encouraging their outcomes, cannot establish that the regimen would perform similarly in the broader population of patients with metastatic gallbladder cancer, and retrospective designs cannot rule out that healthier or more responsive patients were preferentially selected for the treatment.

For that reason, the authors call for prospective controlled studies with integrated biospecimen collection to definitively evaluate the approach. Until then, the reported outcomes—a 100 percent one-year survival rate, complete responses in over half the patients, and successful conversion surgery—stand as a hypothesis-generating signal for a disease with a poor prognosis once distant metastases develop, rather than as a new standard of care.

Subject of Research: A retrospective study of PD-1 blockade combined with gemcitabine and nab-paclitaxel in lymph-node-dominant metastatic gallbladder cancer, with exploratory single-cell immune profiling.

Article Title: PD-1 blockade plus gemcitabine and nab-paclitaxel in lymph node-dominant metastatic gallbladder cancer: a real-world study and exploratory single-cell analysis

Article References: Jiang, B.-Q., Li, Z.-Y., Gan, W., Zhou, Q., Lin, Y.-N., Kang, K., Xu, X.-S., Chen, D.-J., Liu, Y.-B., Peng, S.-Y., & Wang, X.-A. (2026). PD-1 blockade plus gemcitabine and nab-paclitaxel in lymph node-dominant metastatic gallbladder cancer: a real-world study and exploratory single-cell analysis. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04599-2

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04599-2

Keywords: gallbladder cancer, PD-1 blockade, gemcitabine, nab-paclitaxel, lymph-node metastases, immunotherapy, single-cell transcriptomics, conversion surgery, SEER database, retrospective study, tumor microenvironment, RECIST